NOVAVAX, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.36 USD | -2.13% |
|
+5.83% | +217.50% |
| May. 21 | Novavax: 1st shipment of R21/MatrixM malaria vaccine | CF |
| May. 20 | Global markets live: Apple, Tesla, Pfizer, AstraZeneca, Microsoft... |  |
Financials (USD)
| Sales 2024 * | 952M | Sales 2025 * | 586M | Capitalization | 2.2B |
|---|---|---|---|---|---|
| Net income 2024 * | 18M | Net income 2025 * | -116M | EV / Sales 2024 * | 1.44 x |
| Net cash position 2024 * | 837M | Net cash position 2025 * | 704M | EV / Sales 2025 * | 2.56 x |
| P/E ratio 2024 * |
247
x | P/E ratio 2025 * |
-28.6
x | Employees | 1,543 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.14% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novavax, Inc.
More recommendations
More press releases
More news
| 1 day | -0.51% | ||
| 1 week | +7.15% | ||
| Current month | +256.35% | ||
| 1 month | +268.26% | ||
| 3 months | +191.68% | ||
| 6 months | +177.02% | ||
| Current year | +221.46% |
1 week
12.68
17.40
1 month
3.9017.40
Current year
3.5317.40
1 year
3.5317.40
3 years
3.53277.80
5 years
3.53331.68
10 years
3.53331.68
| Managers | Title | Age | Since |
|---|---|---|---|
John Jacobs
CEO | Chief Executive Officer | 57 | 23-01-22 |
John Trizzino
PSD | President | 64 | 14-03-09 |
James Kelly
DFI | Director of Finance/CFO | 58 | 21-08-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 22-10-28 |
Gregg Alton
BRD | Director/Board Member | 58 | 20-10-31 |
David Mott
BRD | Director/Board Member | 58 | 20-06-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.31% | 17 M€ | +8.31% | - | |
| 0.15% | 0 M€ | 0.00% | - | |
| 0.13% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 15.25 | -2.87% | 8 173 634 |
| 24-05-22 | 15.7 | +5.30% | 30,259,203 |
| 24-05-21 | 14.91 | +0.81% | 16,835,913 |
| 24-05-20 | 14.79 | +13.68% | 14,272,460 |
| 24-05-17 | 13.01 | -9.65% | 13,906,467 |
Delayed Quote Nasdaq, May 23, 2024 at 10:00 am EDT
More quotes
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Companyâs proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Calendar
2024-08-05
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
15.7
USD
Average target price
19.75
USD
Spread / Average Target
+25.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +221.46% | 2.2B | |
| +59.79% | 62.59B | |
| -2.30% | 41.18B | |
| +44.36% | 40.29B | |
| -8.29% | 27.9B | |
| +12.84% | 26.21B | |
| -21.64% | 19.09B | |
| +6.00% | 13.08B | |
| +24.33% | 12.26B | |
| +27.24% | 12.05B |
- Stock Market
- Equities
- NVAX Stock
